Pharmacokinetics of Intravenous Amiodarone in Patients with Impaired Left Ventricular Function
Authors:
- 1 August 1996
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 36 (8) , 720-727
Abstract
To evaluate the potential need for modification of dose regimens of intravenous amiodarone in patients with left ventricular dysfunction, the pharmacokinetics of amiodarone and its active metabolite, desethylamiodarone (DEA), were examined after a single 15‐minute intravenous infusion of amiodarone 5 mg/kg. Three parallel groups of otherwise healthy volunteers with normal (n = 12), moderately impaired (ejection fraction > 30 but ≤45%; n = 6), or severely impaired (ejection fraction ≤ 30%; n = 6) left ventricular function were enrolled in the study. Serial blood samples were obtained over a 76‐day period for estimation of pharmacokinetic parameters. With the exception of the half‐life (t1/2) of DEA, statistical comparisons revealed no significant between‐group differences in pharmacokinetic parameters or correlations between pharmacokinetic parameters and ejection fractions. The t1/2 of DEA was increased by approximately 60% in patients with severe left ventricular dysunction compared with that in patients with moderately impaired and normal left ventricular function. The rate of DEA formation is slow, however, and its concentration relative to amiodarone is low. Therefore, it is unlikely that concentrations of DEA in serum would reach levels that contribute significantly to the pharmacologic activity of amiodarone during short‐term (up to 2 weeks) intravenous amiodarone therapy. Single doses of amiodarone were well tolerated. The results of this study suggest that intravenous amiodarone can be used with appropriate observation to control arrhythmias, regardless of the degree of left ventricular dysfunction.Keywords
This publication has 21 references indexed in Scilit:
- Pharmacology and Pharmacokinetics of AmiodaroneThe Journal of Clinical Pharmacology, 1991
- Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardiaThe American Journal of Cardiology, 1990
- Correlation of amiodarone dosage, heart rate, QT interval and corneal microdeposits with serum amiodarone and desethylamiodarone concentrationsThe American Journal of Cardiology, 1989
- Intravenous amiodarone for the rapid treatment of life-threatening ventricular arrhythmias in critically ill patients with coronary artery diseaseThe American Journal of Cardiology, 1989
- Resting left ventricular ejection fraction in elderly patients without evidence of heart diseaseThe American Journal of Cardiology, 1989
- Use of intravenous amiodarone for emergency treatment of life-threatening ventricular arrhythmiasJACC, 1988
- Clinical Pharmacokinetics in Heart FailureClinical Pharmacokinetics, 1988
- Clinical efficacy and electropharmacology of continuous intravenous amiodarone infusion and chronic oral amiodarone in refractory ventricular tachycardiaThe American Journal of Cardiology, 1984
- Amiodarone pharmacokineticsAmerican Heart Journal, 1983
- Long-term management of sustained, recurrent, symptomatic ventricular tachycardia with amiodarone.Circulation, 1981